[Ip-health] Novartis job ad for Director of Market Access, Latin America

Joana Ramos jdr at ramoslink.info
Thu Oct 7 16:49:52 PDT 2010

   FYI, a recent ad widely circulated on job boards. Under "Gipap 
program" , SCM stands for  "shared contribution model" which means 
phase-out of  drug donation to sharing of the cost, either by 3rd party 
payors and/or patients.


  Director Market Access Job

Company - Novartis
Location - *na, New Jersey US *
Job Code - 69564BR
Position - Full Time
Job First Active on: Saturday, September 25, 2010



> Main Priorities for the role:
> Pricing:
> Proactively collaborate/align with Global MALT team to better 
> support/develop smart pricing strategies for LATAM Region in support 
> to New Products and New Indications maintaining alignment with 
> sub-regions.
> Access/Commercial:
> Proactively collaborate/align with Global MALT team to better 
> support/develop Innovative Access/Commercial Models suitable for our 
> LATAM Region.
> Team Integration:
> Collaborate for a successfully integration with Marketing/Medical as 
> well as other key functions to assure Access LATAM Strategies 
> implementation and execution.
> Gipap Program:
> Direct and coordinate program in LATAM Region supporting sub-regions. 
> Lead efforts to convert existing programs to novel, sustainable SCMs 
> models across region.
> .Patient Advocacy:
> Support LATAM Countries and sub-regions to develop Patient Advocacy 
> Groups to empower patients' access to novel medicines while increasing 
> capabilities and impact of patient group's actions. Maintain Patient 
> Access activities and further develop relationships with key 
> pan-regional patient advocacy groups such as the Alianza Latina, 
> American Cancer Society, Life Raft Group and the Max Foundation.

> Success in the position will be measured by:
> .Ability to support LATAM Access strategies across LATAM Region to 
> successfully identify access gaps for Base Business and New -to be 
> launched- products, assuring formulary inclusion and reimbursement 
> which will be a primary KPI measure of performance, driven by novel 
> pricing strategies and contributing to construct tactics that will 
> drive uptake at country level.
> .The protection of the business against major market developments such 
> as reference pricing, reimbursement refusal, unfavorable pricing or 
> penetration of substandard copies which threaten the safety and 
> wellbeing of cancer patients.
> .The achievement of Company's financial objectives.
> .The Company's image credibility and trust within the LATAM Region 
> with key KDM's. 

Joana Ramos, MSW
Cancer Resources & Advocacy
Seattle WA USA

More information about the Ip-health mailing list